ENYO Pharma pursues its international strategy and opens a new subsidiary in Australia
ENYO Pharma has opened its first wholly owned subsidiary in Australia. This office will be our new center to manage clinical trials in the Asia-Pacific region. ENYO Pharma has based its innovation on mimicking virus strategies to discover new cellular targets and develop drug candidates in infectious diseases and beyond.
Read next in 'Latest news'
- Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
- New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
- New publication : An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters
- Swiss NASH Foundation sponsorship
- ENYO Pharma in the Top 50 of the EIC ScalingUp List